دورية أكاديمية
Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
| العنوان: | Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. |
|---|---|
| المؤلفون: | Hwang EC; Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South., Jung JH, Borofsky M, Kim MH, Dahm P |
| المصدر: | The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2019 Feb 13; Vol. 2. Cochrane AN: CD013143. Date of Electronic Publication: 2019 Feb 13. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : Chichester, West Sussex, England : Wiley Original Publication: Oxford, U.K. ; Vista, CA : Update Software, |
| مواضيع طبية MeSH: | Water*, Lower Urinary Tract Symptoms/*surgery , Prostate/*surgery , Prostatic Hyperplasia/*surgery , Robotic Surgical Procedures/*methods, Aged ; Aged, 80 and over ; Ejaculation ; Humans ; Lower Urinary Tract Symptoms/etiology ; Male ; Middle Aged ; Organ Size ; Penile Erection ; Prostate/pathology ; Prostatic Hyperplasia/complications ; Quality of Life ; Retreatment/statistics & numerical data ; Surgery, Computer-Assisted/methods ; Transurethral Resection of Prostate |
| مستخلص: | Background: New, minimally invasive surgeries have emerged as alternatives to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Aquablation is a novel, minimally invasive, water-based therapy, combining image guidance and robotics for the removal of prostatic tissue. Objectives: To assess the effects of Aquablation for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Search Methods: We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to 11 February 2019, with no restrictions on the language or status of publication. Selection Criteria: We included parallel-group randomised controlled trials (RCTs) and cluster-RCTs, as well as non-randomised observational prospective studies with concurrent comparison groups in which participants with BPH who underwent Aquablation. Data Collection and Analysis: Two review authors independently assessed studies for inclusion at each stage, and undertook data extraction and 'Risk of bias' and GRADE assessments of the certainty of the evidence. We considered review outcomes measured up to and including 12 months after randomisation as short-term and beyond 12 months as long-term. Main Results: We included one RCT with 184 participants comparing Aquablation to TURP. The mean age and International Prostate Symptom Score were 65.9 years and 22.6, respectively. The mean prostate volume was 53.2 mL. We only found short-term data for all outcomes based on a single randomised trial.Primary outcomesUp to 12 months, Aquablation likely results in a similar improvement in urologic symptom scores to TURP (mean difference (MD) -0.06, 95% confidence interval (CI) -2.51 to 2.39; participants = 174; moderate-certainty evidence). We downgraded the evidence certainty by one level due to study limitations. Aquablation may also result in similar quality of life when compared to TURP (MD 0.27, 95% CI -0.24 to 0.78; participants = 174, low-certainty evidence). We downgraded the evidence certainty by two levels due to study limitations and imprecision. Aquablation may result in little to no difference in major adverse events (risk ratio (RR) 0.84, 95% CI 0.31 to 2.26; participants = 181, very low-certainty evidence) but we are very uncertain of this finding. This would correspond to 15 fewer major adverse events per 1000 participants (95% CI 64 fewer to 116 more). We downgraded the evidence certainty by one level for study limitations and two levels for imprecision.Secondary outcomesUp to 12 months, Aquablation may result in little to no difference in retreatments (RR 1.68, 95% CI 0.18 to 15.83; participants = 181, very low-certainty evidence) but we are very uncertain of this finding. This would correspond to 10 more retreatments per 1000 participants (95% CI 13 fewer to 228 more). We downgraded the evidence certainty by one level due to study limitations and two levels for imprecision.Aquablation may result in little to no difference in erectile function as measured by International Index of Erectile Function questionnaire Erectile Function domain compared to TURP (MD 2.31, 95% CI -0.63 to 5.25; participants = 64, very low-certainty evidence), and may cause slightly less ejaculatory dysfunction than TURP, as measured by Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MD 2.57, 95% CI 0.60 to 4.53; participants = 121, very low-certainty evidence). However, we are very uncertain of both findings. We downgraded the evidence certainty by two levels due to study limitations and one level for imprecision for both outcomes.We did not find other prospective, comparative studies comparing Aquablation to TURP or other procedures such as laser ablation, enucleation, or other minimally invasive therapies. Authors' Conclusions: Based on short-term (up to 12 months) follow-up, the effect of Aquablation on urological symptoms is probably similar to that of TURP (moderate-certainty evidence). The effect on quality of life may also be similar (low-certainty evidence). We are very uncertain whether patients undergoing Aquablation are at higher or lower risk for major adverse events (very low-certainty evidence). We are very uncertain whether Aquablation may result in little to no difference in erectile function but offer a small improvement in preservation of ejaculatory function (both very low-certainty evidence). These conclusions are based on a single study of men with a prostate volume up to 80 mL in size. Longer-term data and comparisons with other modalities appear critical to a more thorough assessment of the role of Aquablation for the treatment of LUTS in men with BPH. |
| References: | Int J Urol. 1997 Jan;4(1):40-6. (PMID: 9179665) Scand J Urol Nephrol. 1979;13(2):137-42. (PMID: 90380) PLoS Med. 2009 Jul 21;6(7):e1000100. (PMID: 19621070) Eur Urol. 2017 Dec;72(6):986-997. (PMID: 28734706) Cochrane Database Syst Rev. 2020 Mar 25;3:CD013251. (PMID: 32212174) Control Clin Trials. 1989 Dec;10(4):407-15. (PMID: 2691207) J Urol. 2006 Apr;175(4):1422-6; discussion 1426-7. (PMID: 16516013) J Urol. 2008 Jul;180(1):246-9. (PMID: 18499179) J Endourol. 2015 Jan;29(1):63-9. (PMID: 25000418) Cochrane Database Syst Rev. 2020 Dec 19;12:CD012867. (PMID: 33368143) Rev Urol. 2015;17(2):51-7. (PMID: 27222640) Int J Impot Res. 2008 Dec;20 Suppl 3:S11-8. (PMID: 19002119) J Endourol. 2010 Dec;24(12):2051-7. (PMID: 20964486) Urology. 2015 Oct;86(4):721-5. (PMID: 26276574) Eur Urol Focus. 2018 Jan;4(1):28-31. (PMID: 29748094) BJU Int. 2016 Jun;117(6):923-9. (PMID: 26477826) Can J Urol. 2017 Aug;24(4):8937-8940. (PMID: 28832316) Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919) BJU Int. 2019 Aug;124(2):321-328. (PMID: 30734990) World J Urol. 2011 Aug;29(4):423-7. (PMID: 21305303) Cochrane Database Syst Rev. 2019 Feb 13;2:CD013143. (PMID: 30759311) Urology. 2007 May;69(5):805-9. (PMID: 17482908) Ther Adv Urol. 2018 Feb 26;10(6):183-188. (PMID: 29899759) Ann Surg. 2019 Feb;269(2):211-220. (PMID: 29697448) Res Rep Urol. 2015 Aug 19;7:125-36. (PMID: 26317083) J Urol. 2011 May;185(5):1793-803. (PMID: 21420124) J Urol. 2013 Mar;189(3):987-92. (PMID: 23017510) Urology. 2019 Mar;125:169-173. (PMID: 30552937) World J Urol. 2019 Jul;37(7):1369-1375. (PMID: 30288598) Eur Urol. 2014 Jun;65(6):1211-7. (PMID: 24486308) Cochrane Database Syst Rev. 2019 Dec 3;12:CD009629. (PMID: 31792928) Res Synth Methods. 2013 Mar;4(1):49-62. (PMID: 26053539) BJU Int. 2019 Sep;124(3):368-369. (PMID: 31436038) J Clin Epidemiol. 2011 Dec;64(12):1311-6. (PMID: 21802902) BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354) Cochrane Database Syst Rev. 2019 May 25;5:CD012832. (PMID: 31128077) World J Urol. 2019 Feb;37(2):299-308. (PMID: 29967947) J Urol. 1997 Jan;157(1):10-4; discussion 14-5. (PMID: 8976204) J Clin Epidemiol. 2011 Dec;64(12):1283-93. (PMID: 21839614) J Endourol. 2014 Jul;28(7):831-40. (PMID: 24517323) Eur Urol. 2010 Sep;58(3):450-6. (PMID: 20554374) BJU Int. 2014 Jan;113(1):24-35. (PMID: 24053602) Urology. 2004 Oct;64(4):777-82. (PMID: 15491719) Ann Surg. 2004 Aug;240(2):205-13. (PMID: 15273542) J Urol. 2017 Jun;197(6):1565-1572. (PMID: 28111300) Healthc (Amst). 2015 Mar;3(1):43-8. (PMID: 26179588) J Urol. 1995 Nov;154(5):1770-4. (PMID: 7563343) Korean J Urol. 2012 Mar;53(3):139-48. (PMID: 22468207) J Urol. 1992 Nov;148(5):1549-57; discussion 1564. (PMID: 1279218) J Urol. 2018 Sep;200(3):612-619. (PMID: 29775639) BJU Int. 2015 May;115(5):678-9. (PMID: 25885560) Rev Urol. 2008 Winter;10(1):14-25. (PMID: 18470272) BJU Int. 2015 Feb;115(2):308-16. (PMID: 24825577) J Urol. 2018 May;199(5):1252-1261. (PMID: 29360529) BJU Int. 2019 Jan;123(1):106-112. (PMID: 29694702) Eur Urol. 2011 Nov;60(5):1010-6. (PMID: 21855209) BJU Int. 2019 Apr;123(4):651-660. (PMID: 29862630) Health Qual Life Outcomes. 2013 Jul 01;11:109. (PMID: 23815754) Eur Urol Focus. 2018 Jan;4(1):43-45. (PMID: 29803559) Can Urol Assoc J. 2019 May;13(5):E113-E118. (PMID: 30332589) J Urol. 2014 Jan;191(1):130-7. (PMID: 23770136) Urology. 1997 Jun;49(6):822-30. (PMID: 9187685) BMJ. 2008 May 3;336(7651):995-8. (PMID: 18456631) J Clin Epidemiol. 2011 Apr;64(4):383-94. (PMID: 21195583) Med Devices (Auckl). 2016 May 19;9:115-23. (PMID: 27274321) Int J Urol. 2015 Nov;22(11):982-90. (PMID: 26193757) Can J Urol. 2018 Jun;25(3):9317-9322. (PMID: 29900819) Urol Clin North Am. 2016 Aug;43(3):289-97. (PMID: 27476122) Adv Ther. 2017 Aug;34(8):1953-1965. (PMID: 28687936) BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) World J Urol. 2019 Jul;37(7):1361-1368. (PMID: 30370457) |
| المشرفين على المادة: | 059QF0KO0R (Water) |
| تواريخ الأحداث: | Date Created: 20190214 Date Completed: 20190412 Latest Revision: 20210615 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6373984 |
| DOI: | 10.1002/14651858.CD013143.pub2 |
| PMID: | 30759311 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1469-493X |
|---|---|
| DOI: | 10.1002/14651858.CD013143.pub2 |